Sarepta Therapeutics, Inc. (SRPT)
| Market Cap | 10.00B |
| Revenue (ttm) | 1.64B |
| Net Income (ttm) | 121.85M |
| Shares Out | 95.52M |
| EPS (ttm) | 1.22 |
| PE Ratio | 85.81 |
| Forward PE | 10.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,229,655 |
| Open | 102.88 |
| Previous Close | 104.54 |
| Day's Range | 102.16 - 105.98 |
| 52-Week Range | 78.67 - 173.25 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 182.00 (+73.88%) |
| Earnings Date | Nov 6, 2024 |
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping... [Read more]
Financial Performance
In 2023, Sarepta Therapeutics's revenue was $1.24 billion, an increase of 33.26% compared to the previous year's $933.01 million. Losses were -$535.98 million, -23.81% less than in 2022.
Financial StatementsAnalyst Forecast
According to 21 analysts, the average rating for SRPT stock is "Strong Buy." The 12-month stock price forecast is $182.0, which is an increase of 73.88% from the latest price.
News
Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step
Sarepta Therapeutics, Inc. reported Q3 2024 net product revenues of $429.8 million, a 39% year-over-year increase, driven by strong sales of ELEVIDYS and other DMD treatments. The company is advancing...
Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communic...
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2024. “I...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2024 (the “Grant Date”) th...
Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the Nasd...
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the 29th Annual Congress of the World Muscle So...
Sarepta Therapeutics Muscles Up In DMD Race
Sarepta's Elevidys received expanded FDA approval to treat both ambulatory and non-ambulatory DMD patients aged four and above. Although Elevidys missed its primary endpoint, it demonstrated success o...
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its B...
Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholar...
Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fi...
Biotech Stock Flashing Bull Signal
Sarepta Therapeutics (SRPT) staged quite a slide after its June 21 three-year high of $173.25, closing six of the last seven weeks lower. The shares are in positive territory so far this week, however...
Sarepta Therapeutics, Inc. (SRPT) Q2 2024 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations & Corporate Communicatio...
Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2024. “...
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2024 financial results after the Nas...
Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Sarepta Therapeutics, Inc. is a leader in DMD treatment, with recent FDA approval for SRP-9001 gene therapy across all age groups. Despite a recent stock pullback, the company reported strong revenue ...
Will Elevidys Approval Make Sarepta Stock An Acquisition Target?
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, was up 30% on Frid...
Sarepta Therapeutics: Pushing The Edge And Creating The Horizon
Sarepta Therapeutics excels in rare disease therapies using RNA, gene editing, and gene therapies, with significant revenue growth driven by ELEVIDYS gene therapy approval. Despite missing the primary...
Sarepta CEO on what's next after expanded muscular dystrophy drug approval
Douglas Ingram, Sarepta CEO, joins 'Fast Money' to talk FDA approval of Elevidys and its impact on the company's stock.
TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval
Ritu Baral, TD Cowen Sr. Biotechnology Analyst, joins 'Closing Bell Overtime' to talk Sarepta's approval from the FDA for its Duchenne gene therapy and how it drove the stock to its best trading day i...
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Shares of Catalent Inc CTLT, which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million.
Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval
SAN DIEGO--(BUSINESS WIRE)--Wall Street Beats is pleased to announce an investor conference call with Doug Ingram, CEO of Sarepta Therapeutics, following the landmark FDA approval expanding the label ...
Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says
On Thursday, the FDA approved the labeled indication for Sarepta Therapeutics Inc's SRPT Elevidys (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) who ...
Sarepta (SRPT) Soars on FDA Approval on Muscular Dystrophy Treatment
Sarepta (SRPT) soars after the FDA approves expanded use of their Muscular Dystrophy treatment. Jenny Horne weighs in on this story.
Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug
Sarepta Therapeutics' gene therapy received expanded US approval to include more children with a deadly muscle disease. The treatment's approval was widened for use in patients who are at least 4 year...